| RS104894563 |
G6PC1
|
Health Risk |
Pathogenic/Likely pathogenic |
Glycogen storage disease due to glucose-6-phosphatase deficiency type IA, Glycogen storage disease due to glucose-6-phosphatase deficiency type IA |
| RS104894565 |
G6PC1
|
Health Risk |
Pathogenic |
Glycogen storage disease due to glucose-6-phosphatase deficiency type IA, Glycogen storage disease due to glucose-6-phosphatase deficiency type IA |
| RS104894566 |
G6PC1
|
Health Risk |
Pathogenic |
Glycogen storage disease due to glucose-6-phosphatase deficiency type IA, Glycogen storage disease due to glucose-6-phosphatase deficiency type IA |
| RS104894567 |
G6PC1
|
Health Risk |
Pathogenic/Likely pathogenic |
Glycogen storage disease due to glucose-6-phosphatase deficiency type IA, Glycogen storage disease due to glucose-6-phosphatase deficiency type IA |
| RS104894568 |
G6PC1
|
Health Risk |
Pathogenic/Likely pathogenic |
Glycogen storage disease due to glucose-6-phosphatase deficiency type IA, Glycogen storage disease due to glucose-6-phosphatase deficiency type IA |
| RS104894569 |
G6PC1
|
Health Risk |
Pathogenic |
Glycogen storage disease due to glucose-6-phosphatase deficiency type IA, Glycogen storage disease due to glucose-6-phosphatase deficiency type IA |
| RS104894571 |
G6PC1
|
Health Risk |
Conflicting classifications of pathogenicity |
Glycogen storage disease due to glucose-6-phosphatase deficiency type IA, Glycogen storage disease due to glucose-6-phosphatase deficiency type IA |
| RS104894572 |
GALK1
|
Health Risk |
Pathogenic |
Deficiency of galactokinase, Deficiency of galactokinase |
| RS104894574 |
HCRT
|
Health Risk |
Pathogenic |
Narcolepsy 1, Narcolepsy 1 |
| RS104894575 |
KCNJ2
|
Health Risk |
Pathogenic |
Andersen Tawil syndrome, Congenital long QT syndrome |
| RS104894576 |
GALK1
|
Health Risk |
Conflicting classifications of pathogenicity |
Deficiency of galactokinase, Deficiency of galactokinase |
| RS104894577 |
GALK1
|
Health Risk |
Pathogenic |
Deficiency of galactokinase, Deficiency of galactokinase |
| RS104894578 |
KCNJ2
|
Health Risk |
Pathogenic/Likely pathogenic |
Andersen Tawil syndrome, Congenital long QT syndrome |
| RS104894579 |
KCNJ2
|
Health Risk |
Pathogenic |
Andersen Tawil syndrome, Congenital long QT syndrome |
| RS104894580 |
KCNJ2
|
Health Risk |
Pathogenic |
Andersen Tawil syndrome, Congenital long QT syndrome |
| RS104894581 |
KCNJ2
|
Health Risk |
Likely pathogenic |
Congenital long QT syndrome, Andersen Tawil syndrome |
| RS104894582 |
KCNJ2
|
Health Risk |
Pathogenic |
Andersen Tawil syndrome, Congenital long QT syndrome |
| RS104894583 |
KCNJ2
|
Health Risk |
Likely pathogenic |
Andersen Tawil syndrome, Congenital long QT syndrome |
| RS104894584 |
KCNJ2
|
Health Risk |
Pathogenic |
Short QT syndrome type 3, Short QT syndrome |
| RS104894585 |
KCNJ2
|
Health Risk |
Pathogenic |
Andersen Tawil syndrome, Congenital long QT syndrome |
| RS104894586 |
MPDU1
|
Health Risk |
Conflicting classifications of pathogenicity |
MPDU1-congenital disorder of glycosylation, MPDU1-congenital disorder of glycosylation |
| RS104894587 |
MPDU1
|
Health Risk |
Pathogenic |
MPDU1-congenital disorder of glycosylation, MPDU1-congenital disorder of glycosylation |
| RS104894588 |
MPDU1
|
Health Risk |
Pathogenic |
MPDU1-congenital disorder of glycosylation, MPDU1-congenital disorder of glycosylation |
| RS104894589 |
MPDU1
|
Health Risk |
Pathogenic |
MPDU1-congenital disorder of glycosylation, MPDU1-congenital disorder of glycosylation |
| RS104894590 |
NAGLU
|
Health Risk |
Likely pathogenic |
Mucopolysaccharidosis, MPS-III-B |
| RS104894591 |
NAGLU
|
Health Risk |
Pathogenic |
Mucopolysaccharidosis, MPS-III-B |
| RS104894592 |
NAGLU
|
Health Risk |
Pathogenic/Likely pathogenic |
Mucopolysaccharidosis, MPS-III-B |
| RS104894593 |
NAGLU
|
Health Risk |
Conflicting classifications of pathogenicity |
Mucopolysaccharidosis, MPS-III-B |
| RS104894594 |
NAGLU
|
Health Risk |
Pathogenic |
Mucopolysaccharidosis, MPS-III-B |
| RS104894595 |
NAGLU
|
Health Risk |
Pathogenic/Likely pathogenic |
Mucopolysaccharidosis, MPS-III-B |
| RS104894596 |
NAGLU
|
Health Risk |
Pathogenic |
Mucopolysaccharidosis, MPS-III-B |
| RS104894597 |
NAGLU
|
Health Risk |
Pathogenic |
Mucopolysaccharidosis, MPS-III-B |
| RS104894598 |
NAGLU
|
Health Risk |
Pathogenic/Likely pathogenic |
Mucopolysaccharidosis, MPS-III-B |
| RS104894599 |
NAGLU
|
Health Risk |
Pathogenic |
Mucopolysaccharidosis, MPS-III-B |
| RS104894600 |
NAGLU
|
Health Risk |
Likely pathogenic |
Charcot-Marie-Tooth disease axonal type 2V, Mucopolysaccharidosis |
| RS104894601 |
NAGLU
|
Health Risk |
Likely pathogenic |
Mucopolysaccharidosis, MPS-III-B |
| RS104894602 |
NOG
|
Health Risk |
Pathogenic/Likely pathogenic |
Proximal symphalangism 1A, Tarsal-carpal coalition syndrome |
| RS104894603 |
NOG
|
Health Risk |
Pathogenic |
Symphalangism-brachydactyly syndrome, Symphalangism-brachydactyly syndrome |
| RS104894604 |
NAGS
|
Health Risk |
Pathogenic |
Hyperammonemia, type III |
| RS104894605 |
NAGS
|
Health Risk |
Likely pathogenic |
Hyperammonemia, type III |
| RS104894606 |
NAGS
|
Health Risk |
Pathogenic |
Hyperammonemia, type III |
| RS104894607 |
NAGS
|
Health Risk |
Pathogenic |
Hyperammonemia, type III |
| RS104894608 |
NOG
|
Health Risk |
Pathogenic |
Proximal symphalangism 1A, Proximal symphalangism 1A |
| RS104894609 |
NOG
|
Health Risk |
Pathogenic |
Proximal symphalangism 1A, Proximal symphalangism 1A |
| RS104894610 |
NOG
|
Health Risk |
Conflicting classifications of pathogenicity |
Tarsal-carpal coalition syndrome, Tarsal-carpal coalition syndrome |
| RS104894611 |
NOG
|
Health Risk |
Pathogenic/Likely pathogenic |
Tarsal-carpal coalition syndrome, Proximal symphalangism 1A |
| RS104894612 |
NOG
|
Health Risk |
Pathogenic |
Proximal symphalangism 1A, Proximal symphalangism 1A |
| RS104894613 |
NOG
|
Health Risk |
Pathogenic |
Proximal symphalangism 1A, Proximal symphalangism 1A |
| RS104894614 |
NOG
|
Health Risk |
Pathogenic |
Stapes ankylosis with broad thumbs and toes, Stapes ankylosis with broad thumbs and toes |
| RS104894615 |
NOG
|
Health Risk |
Likely pathogenic |
Symphalangism-brachydactyly syndrome, Inborn genetic diseases |
| RS104894616 |
PEX12
|
Health Risk |
Pathogenic |
Peroxisome biogenesis disorder 3A (Zellweger), Peroxisome biogenesis disorder 3A (Zellweger) |
| RS104894617 |
PMP22
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease, type IA |
| RS104894618 |
PMP22
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease, type IA |
| RS104894619 |
PMP22
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary liability to pressure palsies, Charcot-Marie-Tooth disease |
| RS104894620 |
PMP22
|
Health Risk |
Likely pathogenic |
DEJERINE-SOTTAS SYNDROME, AUTOSOMAL DOMINANT |
| RS104894621 |
PMP22
|
Health Risk |
Pathogenic |
DEJERINE-SOTTAS SYNDROME, AUTOSOMAL DOMINANT |
| RS104894622 |
PMP22
|
Health Risk |
Pathogenic |
DEJERINE-SOTTAS SYNDROME, AUTOSOMAL DOMINANT |
| RS104894623 |
PMP22
|
Health Risk |
Conflicting classifications of pathogenicity |
Charcot-Marie-Tooth disease type 1E, Charcot-Marie-Tooth disease |
| RS104894624 |
PMP22
|
Health Risk |
Pathogenic/Likely pathogenic |
DEJERINE-SOTTAS SYNDROME, AUTOSOMAL DOMINANT |
| RS104894625 |
PMP22
|
Health Risk |
Pathogenic |
Hereditary liability to pressure palsies, Charcot-Marie-Tooth disease |
| RS104894626 |
PMP22
|
Health Risk |
Likely pathogenic |
Charcot-Marie-Tooth disease type 1E, Charcot-Marie-Tooth disease |
| RS104894627 |
PMP22
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease, type 1a |
| RS104894629 |
PNPO
|
Health Risk |
Pathogenic/Likely pathogenic |
Pyridoxal phosphate-responsive seizures, Pyridoxal phosphate-responsive seizures |
| RS104894630 |
SCO1
|
Health Risk |
Pathogenic/Likely pathogenic |
Mitochondrial complex IV deficiency, nuclear type 4 |
| RS104894631 |
PNPO
|
Health Risk |
Pathogenic |
Pyridoxal phosphate-responsive seizures, Pyridoxal phosphate-responsive seizures |
| RS104894632 |
POLG2
|
Health Risk |
Likely pathogenic |
Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 4 |
| RS104894634 |
RAI1
|
Health Risk |
Pathogenic |
Smith-Magenis syndrome, Smith-Magenis syndrome |
| RS104894635 |
SGSH
|
Health Risk |
Conflicting classifications of pathogenicity |
Mucopolysaccharidosis, MPS-III-A |
| RS104894636 |
SGSH
|
Health Risk |
Likely pathogenic |
Mucopolysaccharidosis, MPS-III-A |
| RS104894637 |
SGSH
|
Health Risk |
Conflicting classifications of pathogenicity |
Mucopolysaccharidosis, MPS-III-A |
| RS104894638 |
SGSH
|
Health Risk |
Pathogenic |
Mucopolysaccharidosis, MPS-III-A |
| RS104894639 |
SGSH
|
Health Risk |
Pathogenic/Likely pathogenic |
Mucopolysaccharidosis, MPS-III-A |
| RS104894640 |
SGSH
|
Health Risk |
Pathogenic/Likely pathogenic |
Mucopolysaccharidosis, MPS-III-A |
| RS104894641 |
SGSH
|
Health Risk |
Pathogenic/Likely pathogenic |
Mucopolysaccharidosis, MPS-III-A |
| RS104894642 |
SGSH
|
Health Risk |
Pathogenic/Likely pathogenic |
Mucopolysaccharidosis, MPS-III-A |
| RS104894643 |
SGSH
|
Health Risk |
Pathogenic/Likely pathogenic |
Mucopolysaccharidosis, MPS-III-A |
| RS104894644 |
SOST
|
Health Risk |
Pathogenic |
Sclerosteosis 1, Sclerosteosis 1 |
| RS104894645 |
SOST
|
Health Risk |
Pathogenic |
Sclerosteosis 1, Sclerosteosis 1 |
| RS104894647 |
SOX9
|
Health Risk |
Pathogenic |
ACAMPOMELIC CAMPOMELIC DYSPLASIA, Camptomelic dysplasia |
| RS104894648 |
TBX4
|
Health Risk |
Pathogenic |
Coxopodopatellar syndrome, Coxopodopatellar syndrome |
| RS104894649 |
TNFRSF13B
|
Health Risk |
Conflicting classifications of pathogenicity |
Immunodeficiency, common variable |
| RS104894650 |
TNFRSF13B
|
Health Risk |
Pathogenic |
Immunodeficiency, common variable |
| RS104894651 |
USH1G
|
Health Risk |
Pathogenic |
Usher syndrome type 1G, Usher syndrome type 1G |
| RS104894652 |
USH1G
|
Health Risk |
Pathogenic |
Usher syndrome type 1G, Usher syndrome type 1G |
| RS104894653 |
WNT3
|
Health Risk |
Pathogenic |
Tetraamelia syndrome 1, Tetraamelia syndrome 1 |
| RS104894655 |
TCAP
|
Health Risk |
Pathogenic/Likely pathogenic |
Autosomal recessive limb-girdle muscular dystrophy type 2G, Hypertrophic cardiomyopathy 25 |
| RS104894656 |
MC2R
|
Health Risk |
Pathogenic |
Glucocorticoid deficiency 1, Glucocorticoid deficiency 1 |
| RS104894657 |
MC2R
|
Health Risk |
Pathogenic |
Glucocorticoid deficiency 1, Glucocorticoid deficiency 1 |
| RS104894658 |
MC2R
|
Health Risk |
Pathogenic |
Glucocorticoid deficiency 1, Glucocorticoid Deficiency |
| RS104894659 |
MC2R
|
Health Risk |
Likely pathogenic |
Glucocorticoid deficiency 1, Glucocorticoid deficiency 1 |
| RS104894660 |
MC2R
|
Health Risk |
Pathogenic/Likely pathogenic |
Glucocorticoid deficiency 1, Glucocorticoid Deficiency |
| RS104894661 |
MC2R
|
Health Risk |
Pathogenic |
Glucocorticoid deficiency 1, Glucocorticoid deficiency 1 |
| RS104894662 |
MC2R
|
Health Risk |
Pathogenic |
Glucocorticoid deficiency 1, Glucocorticoid deficiency 1 |
| RS104894663 |
RAX
|
Health Risk |
Pathogenic |
Isolated microphthalmia 3, Isolated microphthalmia 3 |
| RS104894664 |
TTR
|
Health Risk |
Likely pathogenic |
Amyloidosis, hereditary systemic 1 |
| RS104894665 |
TTR
|
Health Risk |
Pathogenic/Likely pathogenic |
Amyloidosis, hereditary systemic 1 |
| RS104894666 |
AMH
|
Health Risk |
Pathogenic |
Persistent mullerian duct syndrome, type I |
| RS104894667 |
CFD
|
Health Risk |
Pathogenic |
Recurrent Neisseria infections due to factor D deficiency, Recurrent Neisseria infections due to factor D deficiency |
| RS104894671 |
CRX
|
Health Risk |
Pathogenic |
Cone-rod dystrophy 2, Leber congenital amaurosis 7 |
| RS104894672 |
CRX
|
Health Risk |
Pathogenic/Likely pathogenic |
Cone-rod dystrophy 2, Retinal dystrophy |